CD47 and breast carcinoma: Huimin Zhang et al. demonstrated that the antiangiogenic sorafenib induces intratumoural hypoxia that causes HIF-1-dependent induction of breast cancer stem cells and then activates the expression of CD47 for immune evasion (Zhang et al., 2015).